NSE · AARTIDRUGS · Pharmaceuticals
Aarti Drugs Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹632 Cr with net profit ₹45 Cr — a 7.12% net margin, versus 6.4% the period before.
Shareholding
As of 2026-06-30
- Promoter54.43%
- Public33.75%
- FII1.52%
- DII10.29%
1,43,476 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.72× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #5 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,06,654 Cr | 274.97 | 12.31 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,068 Cr | 205.48 | 16.37 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹25,271 Cr | 118.83 | 13.5 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,568 Cr | 129.46 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd.(this company) | ₹3,753 Cr | 67.98 | 2.42 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,715 Cr | 110.8 | 4.72 | 12.98% | 11.5% |
| Hikal Limited | ₹2,730 Cr | 189.21 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,264 Cr | 250.08 | 9.25 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 148.95 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,329 Cr | 67.82 | 3.27 | 17.67% | 13.66% |
AI analysis
AI-generated · google/gemini-2.5-flashAarti Drugs Ltd. has a market capitalization of Rs 3815 Cr, with a PE ratio of 69.09 and an EPS of 21.36. The company reported revenue of Rs 2403.39 Cr with a profit margin of 7.6%. Its 52-week high is Rs 564.05 and 52-week low is Rs 318.95.
Positives
- +The dividend yield is 48%.
- +Return on Equity (ROE) is 12.58%.
- +Return on Capital Employed (ROCE) is 11.5071%.
Negatives
- −Revenue growth for the annual period ending Mar 2025 was -5.6%.
- −The profit margin is 7.6%, relative to the annual revenue of Rs 2403.39 Cr.
- −Promoter pledge stands at 2.47% as of Mar 2026.
- −The PE ratio is 69.09, while the EPS is Rs 21.36.
Financial Performance
Aarti Drugs Ltd. reported an annual revenue of Rs 2403.39 Cr, experiencing a revenue growth of -5.6%. The company's net profit stood at Rs 168.1585 Cr for the annual period ending Mar 2025. Quarterly performance for Mar 2026 shows revenue of Rs 720.3 Cr and a net profit of Rs 55.19 Cr.
Profitability & Returns
The company's profit margin is 7.6%. Return on equity (ROE) is 12.58% and return on capital employed (ROCE) is 11.5071%. The earnings per share (EPS) is reported at Rs 21.36.
Balance Sheet
The debt-to-equity ratio of Aarti Drugs Ltd. is 0.44. The book value per share is Rs 169.7. The company's dividend yield is 48%.
Ownership & Pledges
As of Mar 2026, promoter holding is 55.0273%, with public shareholders holding 33.1769%. Institutional holdings consist of DII at 10.2183% and FII at 1.5775%. There are 144946 shareholders. The promoter pledge is 2.47%.
Regulatory & Surveillance
The company has disclosed a promoter pledge of 2.47%. Specifically, Mirik Rajendra Gogri and Renil Rajendra Gogri have pledged shares amounting to 641814 and 597957 respectively, as of March 31, 2026. The company is not currently under any surveillance.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.